Pivalde, FYI today's top story on Endpoints News.com is entitled " A new way to infiltrate (and destroy) some of the deadliest drug resistant bugs." The company that is advancing their apparently effective molecule ETX 0462 into "human testing" (notice NOT human clinical trials) is called Entasis. Sure hope the Antimicrobial Action Fund leadership are not more impressed with this company's development efforts than with Alterity's success with PBT2 and have them at the top of their funding list. Hopefully, Stamler, Sinclair, Kempler, et.al. are not asleep at the wheel as per usual and are on top of this issue and recognize the urgency involved in promoting, pushing, and advancing PBT2 to the next step in whatever the process and protocol is. Let's hope so.....
ATH Price at posting:
3.0¢ Sentiment: Hold Disclosure: Held
(20min delay)